KPI data tables
Zealand Pharma operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash, cash equivalents and marketable securities |
|---|---|
| H1 2026 | 14,457 |
| YE 2025 | 15,109 |
Source: Zealand Pharma H1 2026 results: cash position DKK 14,457 million versus DKK 15,109 million. Zealand Pharma Company announcement No. 39 / 2026, 13 Aug 2026: https://via.ritzau.dk/files/90446/15088867/497323/en
| Period | Boehringer Ingelheim (survodutide) | Roche (petrelintide, from 2025) | Sanofi (lixisenatide, legacy royalty) | Other partnerships + grants |
|---|---|---|---|---|
| 2024 | 5 | 0 | 40 | 18 |
| 2023 | 224 | 0 | 70 | 49 |
| 2022 | 10 | 0 | 70 | 24 |
| 2021 | 10 | 0 | 80 | 19 |
| 2020 | 149 | 0 | 150 | 54 |
Source: Zealand Pharma annual + half-year reports (zealandpharma.com IR; OMX Copenhagen filings; ZEAL.CO); milestone-receipt company announcements (BI ~EUR 20M 2020, BI ~EUR 30M 2023, Sanofi ~USD 10M 2023); Roche-Zealand petrelintide licensing announcement (March 12, 2025). Total annual revenue matches reported figures; the per-partner split is estimated from disclosed milestone events because Zealand does not itemize partner-level revenue every year. DKK/USD approx 1 USD = ~6.8 DKK.
| Period | Petrelintide Phase 3 initiation milestone | Roche first anniversary payment |
|---|---|---|
| H1 2026 | 3,671 | 798 |
Source: Zealand Pharma H1 2026 results: revenue DKK 4,525 million; Phase 3 initiation USD 575 million (DKK 3,671 million); anniversary USD 125 million (DKK 798 million). https://via.ritzau.dk/files/90446/15088867/497323/en.